Susan LouwBarry JacobsonElizabeth MayneTracey Wiggill2023-02-282023-02-28Louw S, Jacobson BF, Mayne ES, Wiggill TM. The Novel Coronavirus and Haemostatic Abnormalities: Pathophysiology, Clinical Manifestations, and Treatment Recommendations. Adv Exp Med Biol. 2021;1321:173-180. doi:10.1007/978-3-030-59261-5_150065-2598https://hdl.handle.net/10539/34707The COVID-19 pandemic, caused by the SARS-C0V-2 virus, was initially considered and managed in a similar manner to the previous SARS epidemic as they are both caused by coronaviruses. What has now become apparent is that a major cause of morbidity and mortality in COVID-19 is abnormal thrombosis. This thrombosis occurs on a macro- and microvascular level and is unique to this disease. The virus has been demonstrated in the endothelium of the pulmonary alveoli and as such is thought to contribute to the devastating respiratory complications encountered. D-dimer concentrations are frequently raised in COVID to levels not frequently seen previously. The optimal anticoagulation treatment in COVID remains to be determined, and the myriad of pathophysiologic effects caused by this virus in the human host have also yet to be fully elucidated.© The Author(s), under exclusive license to Springer Nature Switzerland AG 2021COVID-19SARS-CoV-2CoagulopathyThrombosisBiomarkersTreatmentSDG-3: Good health and well-beingArticle